Firm launches FDA approved anti-viral nasal spray

A safe and easy to use nasal spray which protects against respiratory viral infection and allergic rhinitis has been launched in the Philippines.

Buergli Pharma, Inc., the local affiliate of Singapore's Wellesta Holdings Pte, Ltd., launched the Bentrio Nasal spray which was approved by the Food and Drug Administration last May.

According to the Buergli, it is made commercially available in partnership with Swiss manufacturer Altamira Therapeutics Ltd.

It said that Bentrio also marketed in European Union countries after its completion of EU Conformity Assessment Procedure, as well as in other Southeast Asian countries including Singapore, Malaysia and Taiwan.

In June, the nasal spray received clearance from the US FDA for the treatment of allergic rhinitis or hay fever.

“This device offers triple mode of action for personal protection. It is drug-free and preservative-free nasal spray that works by forming a thin protective gel in the nasal mucosa,” Buergli said in a statement.

“The electrostatic effect created by the gel binds and traps airborne allergen and viruses. It also moisturizes the inner lining of the nose which supports its natural protective function that can reduce the risk of upper respiratory tract viral infections and promote alleviation of allergic symptoms,” it added.

Meanwhile, a study on human nasal 3D model concluded that the use of Bentrio can reach a maximum of 99% reduction in viral load by 4th day of regular use by the European research companies specializing in immunology and in vitro respiratory solutions, with the support of the Life and Sciences Department of Magna Graecia University.